DocMorris AG · ISIN: CH0042615283 · EQS - Company News

DocMorris accelerates Rx growth

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong increase in new Rx customers OTC growth of 1.9 per cent Pablo Ros Gomez becomes new CTO Closure of the logistics site in Halle (DE) DocMorris' e-prescr...

SIX:DOCM Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News DocMorris AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (1)
Short Selling (UK) (0)
15 October 2024 06:58AM
DocMorris accelerates Rx growth
CH0042615283
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong incr...
DocMorris AG
About the publication
20 August 2024 06:58AM
DocMorris grows in the prescription business and invests incrementally in new Rx customers
CH0042615283
Frauenfeld, 20 August 2024   Press release Ad hoc announcement pursuant to Art. 53 LR DocMorris grows in the prescription business and invests incrementally in new Rx customers Sales of prescription medicines (Rx) grew year-on-year in July Monthly number of new Rx customers quadrupled Break-even achieved excluding eRx in the first half of 20...
DocMorris AG
About the publication
11 July 2024 06:58AM
DocMorris with accelerated and significant eRx growth in new customers, market share and revenue
CH0042615283
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris with accelerated and significant eRx growth in new customers, market share and revenue 11.07.2024 / 06:58 CET/CEST Frauenfeld, 11 July 2024 Press release DocMorris with accelerated and significant eRx growth in new customers, market share and revenue ...
DocMorris AG
About the publication
23 May 2024 06:58AM
Early redemption of the 2.75% Convertible Bonds due 2025
CH0042615283
Frauenfeld, 23 May 2024 Press release Ad hoc announcement pursuant to Art. 53 LR Early redemption of the 2.75% Convertible Bonds due 2025 DocMorris Finance B.V. notifies the bondholders of its convertible bond due in 2025 that it has exercised the early redemption option Notices to convert the Bonds may be deposited with the paying and conversi...
DocMorris AG
About the publication
23 May 2024 06:58AM
Early redemption of the 2.75% Convertible Bonds due 2025
CH0042615283
Frauenfeld, 23 May 2024 Press release Ad hoc announcement pursuant to Art. 53 LR Early redemption of the 2.75% Convertible Bonds due 2025 DocMorris Finance B.V. notifies the bondholders of its convertible bond due in 2025 that it has exercised the early redemption option Notices to convert the Bonds may be deposited with the paying and conversi...
DocMorris AG
About the publication
14 May 2024 07:00AM
DocMorris announces results of Tender Offer
CH0042615283
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024   End of Inside Information Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1901981   End of Announceme...
DocMorris AG
About the publication
08 May 2024 07:00AM
Daniel Wüest becomes new CFO at DocMorris
CH0042615283
Frauenfeld, 8 May 2024 Press release Ad hoc announcement pursuant to Art. 53 LR Daniel Wüest becomes new CFO at DocMorris The Board of Directors of DocMorris AG has appointed Daniel Wüest to succeed Marcel Ziwica as CFO. Daniel Wüest will take over his new role on 1 October 2024. Marcel Ziwica (49) will leave the company at his own request at...
DocMorris AG
About the publication
06 May 2024 07:00AM
DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2025
CH0042615283
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024   End of Inside Information Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1895589   End of Announceme...
DocMorris AG
About the publication
02 May 2024 06:45PM
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich
CH0042615283
DocMorris AG / Key word(s): AGMEGM Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich 02.05.2024 / 18:45 CET/CEST Frauenfeld, 2 May 2024   Press release Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich The shareholders approved the annual rep...
DocMorris AG
About the publication
30 April 2024 07:00AM
Final allocation of DocMorris CHF 200 million Convertible Bonds Offering
CH0042615283
Please find our press release under the following link:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024   End of Inside Information Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1892265   End of Announceme...
DocMorris AG
About the publication
18 April 2024 07:00AM
DocMorris successfully completes the placement of CHF 200 million Convertible Bonds due 2029
CH0042615283
Please find our press release under the following link about the placement of convertible bonds:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024   End of Inside Information Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss Exchange E...
DocMorris AG
About the publication
17 April 2024 05:46PM
DocMorris launches approx. CHF 200 million Convertible Bonds due 2029
CH0042615283
Under the following link you will find our press release about launching an offering of convertible bonds:https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024   End of Inside Information Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss ...
DocMorris AG
About the publication
16 April 2024 06:57AM
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market
CH0042615283
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market 16.04.2024 / 06:57 CET/CEST Frauenfeld, 16 April 2024 Press release DocMorris continues to grow in the first quarter of 2024 and creates digi...
DocMorris AG
About the publication
10 April 2024 07:00AM
DocMorris receives gematik approval for simple digital e-prescription redemption via health card
CH0042615283
Frauenfeld, 10 April 2024   Press release Ad hoc announcement pursuant to Art. 53 LR   DocMorris receives gematik approval for simple digital e-prescription redemption via health card Product and provider approval for e-prescription redemption via eHealth-CardLink from DocMorris successfully completed Roll-out of the fully digital redemptio...
DocMorris AG
About the publication
21 March 2024 06:58AM
Significant earnings improvement in 2023; e-prescription is standard in Germany
CH0042615283
Frauenfeld, 21 March 2024 Press release Ad hoc announcement pursuant to Art. 53 LR Significant earnings improvement in 2023; e-prescription is standard in Germany Revenue and earnings targets for 2023 achieved Inflection point reached in terms of revenue and active customer base Break-even programme successfully continued and basis for sust...
DocMorris AG
About the publication
16 January 2024 06:58AM
DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base
CH0042615283
DocMorris AG / Key word(s): Development of Sales DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base 16.01.2024 / 06:58 CET/CEST Frauenfeld, 16 January 2024 Press release DocMorris achieves significant revenue growth in the fourt...
DocMorris AG
About the publication
22 November 2023 07:37AM
DocMorris optimises organisational structure and prepares for e-prescription growth in Germany
CH0042615283
Frauenfeld, 22 November 2023 Press release Ad hoc announcement pursuant to Art. 53 LRDocMorris optimises organisational structure and prepares for e-prescription growth in Germany Reduction of the Executive Board from six to five members Walter Hess as CEO additionally assumes segment responsibility for Germany; Matthias Peuckert, Head Germany,...
DocMorris AG
About the publication
19 October 2023 06:58AM
DocMorris strengthens path to profitable growth in third quarter; slightly reduced revenue outlook
CH0042615283
Frauenfeld, 19 October 2023 Press release Ad hoc announcement pursuant to Art. 53 LR DocMorris strengthens path to profitable growth in third quarter; slightly reduced revenue outlook Third quarter confirms path to profitable growth and forms basis for revenue increase in the fourth quarter EBITDA outlook narrowed; 2023 revenue expectation sli...
DocMorris AG
About the publication
17 August 2023 06:57AM
Solid basis for sustainable, profitable growth
CH0042615283
Frauenfeld, 17 August 2023 Press release Ad hoc announcement pursuant to Art. 53 LR Half-year result 2023Solid basis for sustainable, profitable growth Revenue and earnings within full-year guidance range Consistent focus on profitability: EBITDA (adjusted) improved by CHF 33.9 million Growth trend reversal in the second quarter of 2023 Sale...
DocMorris AG
About the publication
06 July 2023 06:11PM
DocMorris demands fully digital non-discriminatory access to e-prescriptions
CH0042615283
DocMorris AG / Key word(s): Market Report DocMorris AG: DocMorris demands fully digital non-discriminatory access to e-prescriptions 06.07.2023 / 18:11 CET/CEST Frauenfeld, 6 July 2023   Press release DocMorris demands fully digital non-discriminatory access to e-prescriptions DocMorris files complaint a...
DocMorris AG
About the publication
06 July 2023 06:11PM
DocMorris demands fully digital non-discriminatory access to e-prescriptions
CH0042615283
DocMorris AG / Key word(s): Market Report DocMorris AG: DocMorris demands fully digital non-discriminatory access to e-prescriptions 06.07.2023 / 18:11 CET/CEST Frauenfeld, 6 July 2023   Press release DocMorris demands fully digital non-discriminatory access to e-prescriptions DocMorris files complaint a...
DocMorris AG
About the publication
26 May 2023 05:40PM
DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
CH0042615283
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Canada, Australia or Japan.   Frauenfeld, 26 May 2023   Press release Ad hoc announcement pursuant to A...
DocMorris AG
About the publication
26 May 2023 05:40PM
DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
CH0042615283
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Canada, Australia or Japan.   Frauenfeld, 26 May 2023   Press release Ad hoc announcement pursuant to A...
DocMorris AG
About the publication
12 May 2023 07:00AM
DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
CH0042615283
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Canada, Australia or Japan.   Frauenfeld, 12 May 2023 Press release Ad hoc announcement pursuant to Art. ...
DocMorris AG
About the publication
12 May 2023 07:00AM
DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
CH0042615283
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Canada, Australia or Japan.   Frauenfeld, 12 May 2023 Press release Ad hoc announcement pursuant to Art. ...
DocMorris AG
About the publication
11 May 2023 07:00AM
DOCM (formerly ROSE)
CH0042615283
DocMorris AG / Key word(s): Strategic Company Decision/Miscellaneous New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE) 11.05.2023 / 07:00 CET/CEST Frauenfeld, 11 May 2023   Press release   New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE) As of today, the ticker symbol for the shares of ...
DocMorris AG
About the publication
11 May 2023 07:00AM
DOCM (formerly ROSE)
CH0042615283
DocMorris AG / Key word(s): Strategic Company Decision/Miscellaneous New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE) 11.05.2023 / 07:00 CET/CEST Frauenfeld, 11 May 2023   Press release   New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE) As of today, the ticker symbol for the shares of ...
DocMorris AG
About the publication
04 May 2023 08:45PM
Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)
CH0042615283
Zur Rose Group AG / Key word(s): AGMEGM Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM) 04.05.2023 / 20:45 CET/CEST Frauenfeld, 4 May 2023 Press release Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM) For...
Zur Rose Group AG
About the publication
04 May 2023 08:45PM
Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)
CH0042615283
Zur Rose Group AG / Key word(s): AGMEGM Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM) 04.05.2023 / 20:45 CET/CEST Frauenfeld, 4 May 2023 Press release Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM) For...
Zur Rose Group AG
About the publication
04 May 2023 10:30AM
Zur Rose Group has successfully completed the sale of its Swiss business to Migros
CH0042615283
Frauenfeld, 4 May 2023 Press release Ad hoc announcement pursuant to Art. 53 LR Zur Rose Group has successfully completed the sale of its Swiss business to Migros  The Zur Rose Group has successfully completed the sale of its Swiss business to the Migros subsidiary Medbase today. As the new owner of the Zur Rose Switzerland business, Medbase is ...
Zur Rose Group AG
About the publication
04 May 2023 10:30AM
Zur Rose Group has successfully completed the sale of its Swiss business to Migros
CH0042615283
Frauenfeld, 4 May 2023 Press release Ad hoc announcement pursuant to Art. 53 LR Zur Rose Group has successfully completed the sale of its Swiss business to Migros  The Zur Rose Group has successfully completed the sale of its Swiss business to the Migros subsidiary Medbase today. As the new owner of the Zur Rose Switzerland business, Medbase is ...
Zur Rose Group AG
About the publication
20 April 2023 07:00AM
Revenue in the first quarter 2023 in line with plan
CH0042615283
Zur Rose Group AG / Key word(s): Development of Sales/Quarterly / Interim Statement Zur Rose Group: Revenue in the first quarter 2023 in line with plan 20.04.2023 / 07:00 CET/CEST Frauenfeld, 20 April 2023   Press release Revenue in the first quarter 2023 in line with plan Continued focus on the measures on the path to profit...
Zur Rose Group AG
About the publication
20 April 2023 07:00AM
Revenue in the first quarter 2023 in line with plan
CH0042615283
Zur Rose Group AG / Key word(s): Development of Sales/Quarterly / Interim Statement Zur Rose Group: Revenue in the first quarter 2023 in line with plan 20.04.2023 / 07:00 CET/CEST Frauenfeld, 20 April 2023   Press release Revenue in the first quarter 2023 in line with plan Continued focus on the measures on the path to profit...
Zur Rose Group AG
About the publication
12 April 2023 07:00AM
Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023
CH0042615283
Zur Rose Group AG / Key word(s): AGMEGM Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023 12.04.2023 / 07:00 CET/CEST Frauenfeld, 12 April 2023 Press release Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023 The Zur Rose Group has today published the invitation ...
Zur Rose Group AG
About the publication
12 April 2023 07:00AM
Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023
CH0042615283
Zur Rose Group AG / Key word(s): AGMEGM Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023 12.04.2023 / 07:00 CET/CEST Frauenfeld, 12 April 2023 Press release Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023 The Zur Rose Group has today published the invitation ...
Zur Rose Group AG
About the publication
23 March 2023 07:00AM
Revenue and earnings targets for 2022 achieved; significant step towards profitability
CH0042615283
Frauenfeld, 23 March 2023 Press release Ad hoc announcement pursuant to Art. 53 LR Revenue and earnings targets for 2022 achieved; significant step towards profitability Revenue performance as expected and earnings improve strongly by CHF 59.2 million Sale of Swiss business significantly strengthens the balance sheet Focus on core B2C busin...
Zur Rose Group AG
About the publication
23 March 2023 07:00AM
Revenue and earnings targets for 2022 achieved; significant step towards profitability
CH0042615283
Frauenfeld, 23 March 2023 Press release Ad hoc announcement pursuant to Art. 53 LR Revenue and earnings targets for 2022 achieved; significant step towards profitability Revenue performance as expected and earnings improve strongly by CHF 59.2 million Sale of Swiss business significantly strengthens the balance sheet Focus on core B2C busin...
Zur Rose Group AG
About the publication
03 February 2023 07:00AM
Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany
CH0042615283
  Frauenfeld, 3 February 2023 Press release Ad hoc announcement pursuant to Art. 53 LR   Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany Zur Rose Group sells its Swiss business to the Migros subsidiary Medbase and focuses on developing its B2C core business (with its focal point) in Germany ...
Zur Rose Group AG
About the publication
03 February 2023 07:00AM
Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany
CH0042615283
  Frauenfeld, 3 February 2023 Press release Ad hoc announcement pursuant to Art. 53 LR   Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany Zur Rose Group sells its Swiss business to the Migros subsidiary Medbase and focuses on developing its B2C core business (with its focal point) in Germany ...
Zur Rose Group AG
About the publication
19 January 2023 07:00AM
Revenue target 2022 achieved, EBITDA better than expected
CH0042615283
  Frauenfeld, 19 January 2023   Press release Ad hoc announcement pursuant to Art. 53 LR   Zur Rose Group: Revenue target 2022 achieved, EBITDA better than expected The EBITDA break-even programme 2023 is progressing faster than planned, leading to an increase in the communicated EBITDA target range for 2022 Integration and logisti...
Zur Rose Group AG
About the publication
24 November 2022 05:45PM
Zur Rose Group takes next step towards profitability and further reduces complexity in Germany
CH0042615283
Zur Rose Group AG / Key word(s): Strategic Company Decision Zur Rose Group takes next step towards profitability and further reduces complexity in Germany 24.11.2022 / 17:45 CET/CEST   Frauenfeld, 24 November 2022 Press release   Zur Rose Group takes next step towards profitability and further reduces complexity in Germa...
Zur Rose Group AG
About the publication
24 November 2022 05:45PM
Zur Rose Group takes next step towards profitability and further reduces complexity in Germany
CH0042615283
Zur Rose Group AG / Key word(s): Strategic Company Decision Zur Rose Group takes next step towards profitability and further reduces complexity in Germany 24.11.2022 / 17:45 CET/CEST   Frauenfeld, 24 November 2022 Press release   Zur Rose Group takes next step towards profitability and further reduces complexity in Germa...
Zur Rose Group AG
About the publication
01 November 2022 07:00AM
Procurement and supply chain brought together under the new Chief Operations Officer
CH0042615283
  Frauenfeld, 1 November 2022 Press release Ad hoc announcement pursuant to Art. 53 LR   Procurement and supply chain brought together under the new Chief Operations Officer  Successful integration of medpex Operations in the new logistics centre in Heerlen Kaspar Niklaus appointed new COO – with increased focus on procurement The Zur...
Zur Rose Group AG
About the publication
01 November 2022 07:00AM
Procurement and supply chain brought together under the new Chief Operations Officer
CH0042615283
  Frauenfeld, 1 November 2022 Press release Ad hoc announcement pursuant to Art. 53 LR   Procurement and supply chain brought together under the new Chief Operations Officer  Successful integration of medpex Operations in the new logistics centre in Heerlen Kaspar Niklaus appointed new COO – with increased focus on procurement The Zur...
Zur Rose Group AG
About the publication
20 October 2022 05:46PM
Zur Rose Group announces results of Tender Offer
CH0042615283
Frauenfeld, 20 October 2022 Press release Ad hoc announcement pursuant to Art. 53 LR Please find our press release under the following link: https://ir.zurrosegroup.com/en/investor-relations/bonds/tender-offer/ End of Inside Information Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone:...
Zur Rose Group AG
About the publication
20 October 2022 05:46PM
Zur Rose Group announces results of Tender Offer
CH0042615283
Frauenfeld, 20 October 2022 Press release Ad hoc announcement pursuant to Art. 53 LR Please find our press release under the following link: https://ir.zurrosegroup.com/en/investor-relations/bonds/tender-offer/ End of Inside Information Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone:...
Zur Rose Group AG
About the publication
20 October 2022 07:01AM
After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022
CH0042615283
Zur Rose Group AG / Key word(s): 9 Month figures After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022 20.10.2022 / 07:01 CET/CEST Frauenfeld, 20 October 2022   Press release Revenue performance as expected, strong growth once again in Switzerland Roll-out of e-prescri...
Zur Rose Group AG
About the publication
20 October 2022 07:01AM
After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022
CH0042615283
Zur Rose Group AG / Key word(s): 9 Month figures After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022 20.10.2022 / 07:01 CET/CEST Frauenfeld, 20 October 2022   Press release Revenue performance as expected, strong growth once again in Switzerland Roll-out of e-prescri...
Zur Rose Group AG
About the publication
More DocMorris AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 1 23rd June 2020 Capital Fund Management SA SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN